These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9756369)

  • 1. Cost issues in sequential therapy.
    Cooke J
    J Infect; 1998 Jul; 37 Suppl 1():45-50. PubMed ID: 9756369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential antibiotic therapy: the right patient, the right time and the right outcome.
    Davey P; Nathwani D
    J Infect; 1998 Jul; 37 Suppl 1():37-44. PubMed ID: 9756368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions.
    Bailey TC; Ritchie DJ; McMullin ST; Kahn M; Reichley RM; Casabar E; Shannon W; Dunagan WC
    Pharmacotherapy; 1997; 17(2):277-81. PubMed ID: 9085319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomics of antibacterial treatment.
    Davey PG; Malek MM; Parker SE
    Pharmacoeconomics; 1992 Jun; 1(6):409-37. PubMed ID: 10147022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the implications of endogenous resistance to medications.
    Laxminarayan R; Weitzman ML
    J Health Econ; 2002 Jul; 21(4):709-18. PubMed ID: 12146599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the impact of non-inpatient i.v. antibiotic treatment for acute infections on the hospital, primary care services and the patient.
    Parker SE; Nathwani D; O'Reilly D; Parkinson S; Davey PG
    J Antimicrob Chemother; 1998 Sep; 42(3):373-80. PubMed ID: 9786477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial treatment strategies in hospitalized patients: what role for pharmacoeconomics?
    Goldman MP; Nair R
    Cleve Clin J Med; 2007 Aug; 74 Suppl 4():S38-47. PubMed ID: 17847177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programs promoting timely sequential antimicrobial therapy: an American perspective.
    Drew RH
    J Infect; 1998 Jul; 37 Suppl 1():3-9. PubMed ID: 9756363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia.
    Paladino JA
    Can J Hosp Pharm; 1995 Oct; 48(5):276-83. PubMed ID: 10152782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact assessment of Aprokam® compared with unlicensed cefuroxime for prophylaxis of post-cataract surgery endophthalmitis.
    Purslow C; Davey K; Johnson M; Pietri G; Suri G
    BMC Ophthalmol; 2015 Jul; 15():72. PubMed ID: 26152124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmaco-economic aspects of antibiotic therapy in hospitals].
    Delporte JP
    Rev Med Liege; 1998 May; 53(5):279-84. PubMed ID: 9689883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute dental infections managed in an outpatient parenteral antibiotic program setting: prospective analysis and public health implications.
    Connors WJ; Rabie HH; Figueiredo RL; Holton DL; Parkins MD
    BMC Infect Dis; 2017 Mar; 17(1):202. PubMed ID: 28279155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The pharmacoeconomics of treatment of severe infections in intensive care].
    Zambrowski JJ
    Ann Fr Anesth Reanim; 2000 May; 19(5):430-5. PubMed ID: 10874445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription of antibiotics and awareness of antibiotic costs by paediatricians in two hospitals in Greece.
    Maltezou HC; Mougkou K; Iosifidis E; Katerelos P; Roilides E; Theodoridou M
    J Chemother; 2014 Feb; 26(1):26-31. PubMed ID: 24410189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomics of antimicrobial therapy.
    Paladino JA
    Am J Health Syst Pharm; 1999 Nov; 56(22 Suppl 3):S25-8. PubMed ID: 10580738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics of appropriate antimicrobial use.
    Davey P
    Diagn Microbiol Infect Dis; 1995; 22(1-2):225-9. PubMed ID: 7587044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation?
    Coast J; Smith RD; Millar MR
    Health Econ; 1996; 5(3):217-26. PubMed ID: 8817296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of nondrug costs of intravenous antibiotic therapy.
    van Zanten AR; Engelfriet PM; van Dillen K; van Veen M; Nuijten MJ; Polderman KH
    Crit Care; 2003 Dec; 7(6):R184-90. PubMed ID: 14624694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic pharmacoeconomics: an attempt to find the real cost of hospital antibiotic prescribing.
    Kerr JR; Barr JG; Smyth ET; O'Hare J; Bell PM; Callender ME
    Ulster Med J; 1993 Apr; 62(1):50-7. PubMed ID: 8516976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of new antibiotics for the treatment of infections in the emergency department.
    Talan DA
    Ann Emerg Med; 1994 Sep; 24(3):473-89. PubMed ID: 8080145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.